Skip to main content

Table 2 Disproportionality analysis algorithm

From: Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: a safety analysis of the FDA adverse event reporting system

Item

Target AEs

Other AEs

Sums

Target drug

a

b

a + b

Other drugs

c

d

c + d

Sums

a + c

b + d

a + b + c + d